Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group.
about
Chronic lymphocytic leukaemia: an overview of aetiology in light of recent developments in classification and pathogenesisPurine Antagonists for Chronic Lymphocytic LeukaemiaPurine Antagonists for Chronic Lymphocytic LeukaemiaGuidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelinesCombination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemiaThiamine deficiency in patients with B-chronic lymphocytic leukaemia: a pilot studyCladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patientsChronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data.Genetic features of B-cell chronic lymphocytic leukemia.2-Chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia.Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma.Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment.2-Chlorodeoxyadenosine Treatment of Refractory Chronic Lymphocytic Leukemia.New Agents and Strategies in CLL Treatment.The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy.Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia.How I treat CLL up front.Differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis according to clinical outcome: on behalf of the GIMEMA chronic lymphoproliferative diseases working groupRole of fludarabine in hematological malignancies.The role of nucleoside analogues in the treatment of chronic lymphocytic leukemia-lessons learned from prospective randomized trials.The development of marked elevation in white blood cell count does not predict inferior outcome in chronic lymphocytic leukemia.ZAP70 Expression Within del6q21, del11q13 and del17p13 Cytogenetic Subgroups of Iranian Patients with Chronic Lymphocytic LeukemiaThe epidemiological features of lymphoid malignancies in Benin City, Nigeria: a 15 years study.Analysis of alterations of oncogenes and tumor suppressor genes in chronic lymphocytic leukemia.Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemiaNovel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia.Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance.Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational useEffective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism.Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment.A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia.Risk categories and refractory CLL in the era of chemoimmunotherapy.B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome.Loss of p53 and altered miR15-a/16-1MCL-1 pathway in CLL: insights from TCL1-Tg:p53(-/-) mouse model and primary human leukemia cells.Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patientsMonoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical managementSystemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth.A review of pharmacologic options for previously untreated chronic lymphocytic leukemia.Targeting p53-deficient chronic lymphocytic leukemia cells in vitro and in vivo by ROS-mediated mechanism.Monoclonal B-cell lymphocytosis: a reappraisal of its clinical implications.
P2860
Q23917829-D6C95D0F-0DA7-4686-8CC9-BCAE3A0864CCQ24245132-2C46ED81-CEFC-4A32-8E20-0605AE5FF1D4Q24248167-A3339CB8-1539-4121-825E-AD8E87D55B6EQ24616084-1669D8D9-5E62-4D5E-BF96-978A61D4ED75Q24681296-39EDA53A-96C4-47FD-A67A-CFB3E8FA3D74Q28346784-88BFFC5B-1378-4856-8B85-4177D3E53412Q28371742-AD7894E3-7C2E-4DA6-915F-35A642AF5DFAQ30661281-5A5C36DB-95F4-4E6A-ABD6-435488046A08Q30705550-81D51765-1BFF-49A8-97BE-FC7B69A4111EQ33329000-28DD92E9-295B-4B71-948F-134DD832B73CQ33337520-F0597BF4-27D2-415D-93DE-C7EA046A2061Q33344377-AF40F59B-FD26-414D-807D-A80951039084Q33434186-0282AAB0-28C7-47B2-AABB-3DB2ECB299DAQ33434189-89726801-544F-49B1-802E-E02EA9FDC780Q33558740-499BC035-B0A8-409E-A0CA-D0E7E9CB4018Q33886052-B43328DC-67FF-4F5C-B961-425C9A885F94Q34137158-430060C3-FEE4-4310-80F2-83A667F7DAB4Q34543041-567CC510-1EB9-4B2B-9BED-2DB6340F2BBFQ34571439-0BC9B6A2-9381-44F3-9465-7689A527B74CQ34632502-75500B55-0DE4-456C-80D2-3BC49D650400Q34769809-29B70530-2FE3-4D6C-A4A6-1443E215BEE5Q35087595-9AD4254D-F38B-4E6B-A6D0-5733BE41C36DQ35767621-152245F8-2E90-4418-800D-424E7BBAD267Q35834161-FB4A52C2-AA35-491B-920D-AFC89D78632EQ35848136-2499F192-E964-4681-8590-3F208164AFDBQ36135185-D4BF276A-E094-45CF-9215-8BAFB45CCF9BQ36431172-A0275BCE-C26F-4B61-ACC6-DCA17BE42E85Q36768605-B81FA520-1A40-458F-BFA4-E1BD0641E92CQ36843744-1A1BB5BE-05DB-4575-84BC-1F749A49136BQ36961269-C3F0E4C9-DC33-4EF0-9420-D0CFFE5CAEE7Q37112857-7137085A-6A81-48A5-A5D3-9D2EDC629F1DQ37141887-4217835C-351D-434E-9B4D-92C80D5A7CC6Q37176527-A0B0AC92-D08D-40DF-B332-013B72318927Q37251592-742E85F2-335C-451D-933B-1296FC9C017BQ37489992-473E45E1-0D97-473C-846A-67F195B7C52FQ37552813-2FBCA93F-BA9C-49C3-9970-7D82C6DC0D56Q37568665-C186C14A-983F-4068-972D-F146BFCA826FQ37677899-08626E8C-2DAC-4669-A862-E9AE9421E931Q37687622-5BCE73C8-7D59-4998-A998-91BD089F32BBQ37984121-E76F7CC9-376F-4FFF-A135-DE5E2C60AC0F
P2860
Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Guidelines for clinical protoc ...... itute-sponsored working group.
@en
type
label
Guidelines for clinical protoc ...... itute-sponsored working group.
@en
prefLabel
Guidelines for clinical protoc ...... itute-sponsored working group.
@en
P2093
P356
P1476
Guidelines for clinical protoc ...... itute-sponsored working group.
@en
P2093
Bennett JM
Keating MJ
Schiffer CA
P304
P356
10.1002/AJH.2830290307
P577
1988-11-01T00:00:00Z